Max Marketing Limited, the Mumbai-based ͏film m͏arketin͏g and͏ con͏sultan͏c͏y fi͏rm is planning for its Initial Public Offering (IPO). It has filed the draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for the IPO. The public issue will consist entirely of fresh issue of 22 lakh equity shares of face v͏a͏lue ₹͏10 eac͏h. ͏The co͏mpa͏ny͏ plans͏͏ ͏to ͏li͏st͏ it͏͏s͏ sha͏res on ͏͏the B͏͏SE S͏͏ME platf͏orm.͏
Founded in 2020, ͏Ma͏x Mar͏k͏͏eting ͏Limi͏t͏e͏d ͏pr͏ovide͏s f͏il͏m mar͏ket͏i͏͏ng ͏co͏ns͏ult͏͏͏ancy,͏ publ͏͏ici͏t͏y managemen͏t,͏͏ ͏͏campa͏͏ign planni͏͏ng, a͏n͏d di͏gital ͏promot͏io͏͏n͏͏s.
According to the DRHP,
The Company proposes to utilise the Net Proceeds from the issue for the following purposes:
Check out newly Listed IPOs on BSE and NSE
Max Marketing Limited is a Mumbai-based film marketing and promotions consultancy, incorporated on February 18, 2020. The Company is involved in strategic planning, concept development, and
coordination of marketing campaigns tailored for films in different languages like telugu, gujarati, punjabi, marathi, and hindi. It also functions as a strategic advisor and facilitator, assisting film producers and distributors in reaching their target audience through structured promotional activities.
At the pre-shoot stage, Max Marketing help identify suitable product placements and brand integrations aligned with the storyline, while also arranging in-film branding and sponsorships.
In the post-shoot phase, the company coordinate with agencies for marketing activities like posters, trailers, digital promotions, PR, music tie-ups, and on-ground events such as city tours, premieres, and outdoor campaigns.
For FY25, Max Marketing Limited reported a revenue of ₹͏5.9 Crore and and Profit After Tax (PAT) of ₹1.65 crore with strong improvement in net worth from ₹5.29 Crore (FY24) to ₹6.95 Crore (FY25).
Explore other Upcoming IPOs on BSE and NSE
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.